C.P.S.-Pharma GmbH is a mid-sized pharmaceutical trading company headquartered in Beckingen, founded on 06.12.2002 in Dresden; the company employs more than 30 staff. Its core business is wholesale as well as import and export of pharmaceutical products and related goods, in particular biocide products, dietary supplements and medical devices; the company holds a pharmaceutical wholesaler license (§52a AMG), a GDP certificate and ISO 9001 certification. Additional business activities include disinfection and antimicrobial surface coatings as well as rental, sale and franchising of devices from the healthcare sector. Key customer and supplier groups are pharmacies, medical practices, hospitals, nursing homes, practice and medical-supplies dealers and other specialist traders with long-standing business relationships.
Der Großhandel sowie Import und Export von pharmazeutischen Produkten und ähnlichen Erzeugnissen, insbesondere Biozidprodukten, Nahrungsergänzungsmitteln und Medizinprodukten; Die Desinfektion und antimikrobielle Beschichtung von Oberflächen und Räumen; Die Vermietung, der Verkauf und Franchise von hierzu verwendeten Geräten sowie von Geräten aus dem Gesundheitsbereich.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 16111 (as of 23 October 2026)
| Name | Type | City |
|---|---|---|
| Stephan Schommer | Geschäftsführer(in) | Beckingen |
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 16111 (as of 23 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2023 | Rohergebnis€2.4M2 | -€1,900,349 | €8,441,393 | 34 |
| 2022 | Rohergebnis€4.2M2 | €519,271 | €9,467,943 | 38 |
| 2021 | Rohergebnis€4.3M2 | -€1,474,906 | €9,154,138 | 35 |
| 2020 | Rohergebnis€3.3M2 | €98,089 | €7,399,844 | 30 |
| 2019 | small company1 | €300,139 | €5,141,482 | 24 |
| 2018 | small company1 | €393,351 | €5,037,099 | 28 |
| 2017 | ≤ €12M1 | €191,703 | €6,246,993 | 29 |
| 2016 | small company1 | €170,661 | €5,097,173 | 27 |
| 2015 | small company1 | -€295,244 | €4,944,405 | 36 |
| 2014 | ≤ €12M1 | -€298,572 | €6,079,468 | 24 |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 16111 (as of 23 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €1,899,349 | 81.0% |
| Depreciation | €78,702 | 3.4% |
| Interest & Similar | €366,037 | 15.6% |
